Ipsen’s Dysport Likely Impacted By COVID-19 In Q2, But China Sales To Return
Specialty Portfolio Drives Ipsen In First Quarter
Executive Summary
Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.